✦ LIBER ✦

SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial

✍ Scribed by Inagaki, Nobuya; Onouchi, Hitoshi; Sano, Hiroki; Funao, Nobuo; Kuroda, Shingo; Kaku, Kohei

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

TAK-875 versus placebo or glimepiride in

✍ Charles F Burant; Prabhakar Viswanathan; John Marcinak; Charlie Cao; Majid Vakil 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 386 KB

Dutogliptin, a selective DPP4 inhibitor,

✍ H. M. R. Pattzi; S. Pitale; M. Alpizar; C. Bennett; A. M. O’Farrell; J. Li; J. M 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 571 KB

Efficacy and safety of the dipeptidyl pe

✍ Pratley, Richard E.; Reusch, Jane E.-B.; Fleck, Penny R.; Wilson, Craig A.; Mekk 📂 Article 📅 2009 🏛 Informa plc 🌐 English ⚖ 282 KB

Linagliptin, a dipeptidyl peptidase-4 in

✍ Akiko Sarashina; Shogo Sesoko; Mitsuyoshi Nakashima; Naoyuki Hayashi; Atsushi Ta 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 212 KB

Efficacy and safety of adding the dipept

✍ M. A. Nauck; G. C. Ellis; P. R. Fleck; C. A. Wilson; Q. Mekki; for the Aloglipti 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB

The efficacy and safety of the dipeptidy

✍ Robert Frederich, Robert McNeill, Niklas Berglind, Douglas Fleming, Roland Chen 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 239 KB